123 related articles for article (PubMed ID: 9634925)
1. Presence and testosterone influence on the levels of anti- and pro-inflammatory cytokines in lacrimal tissues of a mouse model of Sjögren's syndrome.
Rocha EM; Wickham LA; Huang Z; Toda I; Gao J; da Silveira LA; Sullivan DA
Adv Exp Med Biol; 1998; 438():485-91. PubMed ID: 9634925
[No Abstract] [Full Text] [Related]
2. Comparative influence of steroid hormones and immunosuppressive agents on autoimmune expression in lacrimal glands of a female mouse model of Sjögren's syndrome.
Sato EH; Sullivan DA
Invest Ophthalmol Vis Sci; 1994 Apr; 35(5):2632-42. PubMed ID: 8163351
[TBL] [Abstract][Full Text] [Related]
3. Influence of androgen therapy on lacrimal autoimmune disease in a mouse model of Sjögren's syndrome.
Sullivan DA; Rocha FJ; Sato EH
Adv Exp Med Biol; 1995; 371B():1199-202. PubMed ID: 7502783
[No Abstract] [Full Text] [Related]
4. Lacrimal and salivary gland inflammation in the C3H/Ipr autoimmune strain mouse: a potential mode for Sjögren's syndrome.
Johnson BC; Morton JI; Trune DR
Otolaryngol Head Neck Surg; 1992 Apr; 106(4):394-9. PubMed ID: 1565490
[TBL] [Abstract][Full Text] [Related]
5. Sjögren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease.
Gao J; Killedar S; Cornelius JG; Nguyen C; Cha S; Peck AB
J Autoimmun; 2006 Mar; 26(2):90-103. PubMed ID: 16413168
[TBL] [Abstract][Full Text] [Related]
6. Submandibular and lacrimal gland immunoglobulin in the C3H.MRL-Faslpr autoimmune mouse model of Sjögren's syndrome.
Trune DR; Leedy DA
Laryngoscope; 1998 Nov; 108(11 Pt 1):1729-32. PubMed ID: 9818834
[TBL] [Abstract][Full Text] [Related]
7. Gender and androgen treatment influence the expression of proto-oncogenes and apoptotic factors in lacrimal and salivary tissues of MRL/lpr mice.
Toda I; Wickham LA; Sullivan DA
Clin Immunol Immunopathol; 1998 Jan; 86(1):59-71. PubMed ID: 9434797
[TBL] [Abstract][Full Text] [Related]
8. Different stages of primary Sjogren's syndrome involving lymphotoxin and type 1 IFN.
Shen L; Suresh L; Malyavantham K; Kowal P; Xuan J; Lindemann MJ; Ambrus JL
J Immunol; 2013 Jul; 191(2):608-13. PubMed ID: 23772034
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of androgen analogues in suppressing lacrimal gland inflammation in a mouse model (MRL/lpr) of Sjögren's syndrome.
Rocha FJ; Sato EH; Sullivan BD; Sullivan DA
Adv Exp Med Biol; 1994; 350():697-700. PubMed ID: 8030558
[No Abstract] [Full Text] [Related]
10. A novel NOD-derived murine model of primary Sjögren's syndrome.
Robinson CP; Yamachika S; Bounous DI; Brayer J; Jonsson R; Holmdahl R; Peck AB; Humphreys-Beher MG
Arthritis Rheum; 1998 Jan; 41(1):150-6. PubMed ID: 9433880
[TBL] [Abstract][Full Text] [Related]
11. Androgen stimulation of lacrimal gland function in mouse models of Sjögren's syndrome.
Sullivan DA; Edwards JA
J Steroid Biochem Mol Biol; 1997 Feb; 60(3-4):237-45. PubMed ID: 9191982
[TBL] [Abstract][Full Text] [Related]
12. Influence of sex hormones and genetic predisposition in Sjögren's syndrome: a new clue to the immunopathogenesis of dry eye disease.
Mostafa S; Seamon V; Azzarolo AM
Exp Eye Res; 2012 Mar; 96(1):88-97. PubMed ID: 22227485
[TBL] [Abstract][Full Text] [Related]
13. Impact of androgen therapy in Sjögren's syndrome: hormonal influence on lymphocyte populations and Ia expression in lacrimal glands of MRL/Mp-lpr/lpr mice.
Sato EH; Ariga H; Sullivan DA
Invest Ophthalmol Vis Sci; 1992 Jul; 33(8):2537-45. PubMed ID: 1634351
[TBL] [Abstract][Full Text] [Related]
14. Sjögren's syndrome in mice carrying the Ipr(cg) gene and the therapeutic efficacy of an immunosuppressive agent FK506.
Yang J; Shikata N; Yasuda T; Matsuzawa A; Tsubura A
Pathol Int; 1999 Feb; 49(2):133-40. PubMed ID: 10355966
[TBL] [Abstract][Full Text] [Related]
15. A new animal model for primary Sjögren's syndrome in NFS/sld mutant mice.
Haneji N; Hamano H; Yanagi K; Hayashi Y
J Immunol; 1994 Sep; 153(6):2769-77. PubMed ID: 8077681
[TBL] [Abstract][Full Text] [Related]
16. A novel lacrimal gland autoantigen in the NOD mouse model of Sjögren's syndrome.
Esch TR; Poveromo JD; Aikins MC; Levanos VA
Scand J Immunol; 2002 Mar; 55(3):304-10. PubMed ID: 11940237
[TBL] [Abstract][Full Text] [Related]
17. Primary Sjögren's syndrome and deficiency of ICA69.
Winer S; Astsaturov I; Cheung R; Tsui H; Song A; Gaedigk R; Winer D; Sampson A; McKerlie C; Bookman A; Dosch HM
Lancet; 2002 Oct; 360(9339):1063-9. PubMed ID: 12383988
[TBL] [Abstract][Full Text] [Related]
18. Sjögren's syndrome: immunological response underlying the disease.
Brayer JB; Humphreys-Beher MG; Peck AB
Arch Immunol Ther Exp (Warsz); 2001; 49(5):353-60. PubMed ID: 11798133
[TBL] [Abstract][Full Text] [Related]
19. Androgen-induced suppression of autoimmune disease in lacrimal glands of mouse models of Sjögren's syndrome.
Sullivan DA; Ariga H; Vendramini AC; Rocha FJ; Ono M; Sato EH
Adv Exp Med Biol; 1994; 350():683-90. PubMed ID: 8030556
[No Abstract] [Full Text] [Related]
20. Pathological Analysis of Ocular Lesions in a Murine Model of Sjögren's Syndrome.
Ushio A; Arakaki R; Eguchi H; Hotta F; Yamada A; Kudo Y; Ishimaru N
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
